GHK-Cu · research summary

GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.

Pharmaceutics · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Structured systematic evidence-mapping review
“We conducted a structured systematic evidence-mapping review of PubMed/MEDLINE, Europe PMC, major publisher platforms, ClinicalTrials.gov, backward citation chains, and official European Union, U.S., and ICH regulatory sources from database inception through 12 August 2026.”

Subjects

Glycyl-L-histidyl-L-lysine (GHK) and its copper(II) complex GHK-Cu
“Glycyl-L-histidyl-L-lysine (GHK) and its copper(II) complex GHK-Cu have been studied for matrix remodeling, inflammation, redox regulation, angiogenesis, and tissue repair, yet the literature frequently treats GHK-Cu as a single active ingredient despite formulation-dependent variation in coordination state, speciation, stability, pharmacokinetics, and toxicity.”

Sample size

62 cited sources comprising 44 primary experimental or clinical reports, eight review/contextual reports, one active clinical-trial registry record, and nine regulatory/guidance sources
“At the revision cutoff, the final qualitative corpus comprised 62 cited sources: 44 primary experimental or clinical reports, eight review/contextual reports, one active clinical-trial registry record, and nine regulatory/guidance sources.”

Duration

Database inception through 12 August 2026
“The search was updated from database inception through 12 August 2026.”

Reported findings

Preclinical data support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis, but clinical evidence is sparse and does not meet contemporary active-entity quality standards.
“Preclinical data consistently support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis, but the clinical evidence remains sparse and does not meet contemporary active-entity quality standards.”
Delivery studies often report particle size and bulk release but usually do not resolve molar occupancy, labile copper, or release of intact GHK-Cu versus apo-GHK/free copper.
“Across delivery studies, particle size, polydispersity, encapsulation efficiency, total peptide/copper content, and bulk release are often reported, whereas molar occupancy, labile copper, and release of intact GHK-Cu versus apo-GHK/free copper are usually not resolved.”

Source: PubMed 42797253 · DOI 10.3390/pharmaceutics18091077 · all study summaries

Study type

Structured systematic evidence-mapping review

“We conducted a structured systematic evidence-mapping review of PubMed/MEDLINE, Europe PMC, major publisher platforms, ClinicalTrials.gov, backward citation chains, and official European Union, U.S., and ICH regulatory sources from database inception through 12 August 2026.”

Subjects

Glycyl-L-histidyl-L-lysine (GHK) and its copper(II) complex GHK-Cu

“Glycyl-L-histidyl-L-lysine (GHK) and its copper(II) complex GHK-Cu have been studied for matrix remodeling, inflammation, redox regulation, angiogenesis, and tissue repair, yet the literature frequently treats GHK-Cu as a single active ingredient despite formulation-dependent variation in coordination state, speciation, stability, pharmacokinetics, and toxicity.”

Sample size

62 cited sources comprising 44 primary experimental or clinical reports, eight review/contextual reports, one active clinical-trial registry record, and nine regulatory/guidance sources

“At the revision cutoff, the final qualitative corpus comprised 62 cited sources: 44 primary experimental or clinical reports, eight review/contextual reports, one active clinical-trial registry record, and nine regulatory/guidance sources.”

Reported findings

Preclinical data support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis, but clinical evidence is sparse and does not meet contemporary active-entity quality standards.

“Preclinical data consistently support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis, but the clinical evidence remains sparse and does not meet contemporary active-entity quality standards.”

Delivery studies often report particle size and bulk release but usually do not resolve molar occupancy, labile copper, or release of intact GHK-Cu versus apo-GHK/free copper.

“Across delivery studies, particle size, polydispersity, encapsulation efficiency, total peptide/copper content, and bulk release are often reported, whereas molar occupancy, labile copper, and release of intact GHK-Cu versus apo-GHK/free copper are usually not resolved.”